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Breast cancer and ovarian cancer: State of the art treatment
approachesBreast cancer is the most frequent female cancer, accounting
for 23% of all cancers, and is the leading cause of cancer mor-
tality in women worldwide. An astounding 4.4 million women
are alive today with breast cancer.1 Most of these women
were diagnosed with early-stage (63%) or locally advanced
disease (30%), but approximately 6% presented with meta-
static disease.2 Importantly, nearly half of women presenting
with early-stage disease will ultimately develop metastases,3
making treatment of breast cancer an important worldwide
health care concern.
Ovarian cancer is the seventh most common cause of can-
cer death in women. With 204,000 new cases and 125,000
deaths annually worldwide, it affects fewer women than does
breast cancer,1 but is associated with higher mortality.
The papers in this supplement address state of the art
therapy for breast and ovarian cancers. Information is in-
cluded on HER2-positive and HER2-negative metastatic breast
cancer, early-stage and locally advanced breast cancer in the
elderly, and partially platinum-sensitive relapsed ovarian
cancer.
A recurring theme in each of these state of the art re-
views is the importance of tailoring treatment to unique dis-
ease and patient characteristics such as HER2 status,
hormone-receptor status, toxicities resulting from previous
regimens, relapse-free interval, performance status, and
when applicable, the results of a comprehensive geriatric
assessment.
Anthracyclines and taxanes are the mainstay of antineo-
plastic treatment for breast cancer, with the addition of
trastuzumab in women with HER2-positive disease. A plati-
num-containing combination is the best current treatmentfor ovarian cancer. However, these treatments can be associ-
ated with troublesome toxicity, and resistance eventually
develops in all cases. Alternative strategies, including the
use of less cardiotoxic drugs such as pegylated liposomal
doxorubicin or the anti-HER2 agent lapatinib, are expanding
the number of patients who can benefit from the multiple
lines of treatment that have become a standard strategy in
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